A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. (November 2013)

• Record Type: Journal Article
• Authors: Singh, Neeta; Zangmo, Rinchen; Kumar, Sunesh; Roy, K. K.; Sharma, J. B.; Malhotra, Neena; Vanamail, Perumal
• Is Part Of: Gynecological endocrinology. Volume 29:Number 11(2013:Nov.)
• Page Start: 989
• Page End: 992
• Publication Date: 2013-11
• Subjects: Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2013.824957
• Languages: English
• ISSNs: 0951-3590

Abstract

<abstract> <title>Abstract</title> <p> <italic>Aim</italic>: The aim of this study was to evaluate the role of dehydroepiandrosterone (DHEA) supplementation on the ovarian reserve markers in infertile patients who were poor responders in previous <italic>in vitro</italic> fertilization (IVF) cycles.</p> <p> <italic>Study design</italic>: A prospective clinical trial was conducted on 30 patients with history of poor response in previous IVF cycles. These patients were treated with DHEA, (Tab Eema-D, Corona Remedies Pvt Ltd., Ahmedabad, Gujurat, India) 25 mg thrice a day for four months. Ovarian stimulation was done using the previous protocol. Clinical parameters were measured before and treatment with DHEA. Results were analysed using Student's "<italic>t</italic>" paired test.</p> <p> <italic>Results</italic>: DHEA resulted in a significant increase (<italic>p</italic> < 0.05) in the serum Antimullerian hormone in all age groups (35, 36–38 and >38 years). Peak estradiol level on the day of human chorionic gonadotrophin administration also increased significantly (<italic>p</italic> < 0.05). A significant decrease (<italic>p</italic> < 0.05) was noted in Day 2 follicle-stimulating hormone (FSH) in all age groups. There was no statistically significant difference in the antral follicle count (AFC). Pregnancy rate was 16.7% after treatment. Thus, DHEA has a significant effect in improving the ovarian reserve in poor responders with previously failed IVF cycles. It can help in enhancing clinical pregnancy rate in these patients.</p> </abstract>